{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:36:02Z","timestamp":1784896562173,"version":"3.55.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BH3 mimetics like venetoclax target prosurvival Bcl-2 family proteins and are important therapeutics in the treatment of hematological malignancies. We demonstrate that endogenous Bfl-1 expression can render preclinical lymphoma tumor models insensitive to Mcl-1 and Bcl-2 inhibitors. However, suppression of Bfl-1 alone was insufficient to fully induce apoptosis in Bfl-1\u2013expressing lymphomas, highlighting the need for targeting additional prosurvival proteins in this context. Importantly, we demonstrated that cyclin-dependent kinase 9 (CDK9) inhibitors rapidly downregulate both Bfl-1 and Mcl-1, inducing apoptosis in BH3-mimetic\u2013resistant lymphoma cell lines in vitro and driving in vivo tumor regressions in diffuse large B-cell lymphoma patient-derived xenograft models expressing Bfl-1. These data underscore the need to clinically develop CDK9 inhibitors, like AZD4573, for the treatment of lymphomas using Bfl-1 as a selection biomarker.<\/jats:p>","DOI":"10.1182\/blood.2020008528","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T21:39:39Z","timestamp":1606858779000},"page":"2947-2957","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas"],"prefix":"10.1182","volume":"137","author":[{"given":"Scott","family":"Boiko","sequence":"first","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Proia","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"San Martin","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth P.","family":"Gregory","sequence":"additional","affiliation":[{"name":"Gene Regulation Laboratory, Research Division, Peter MacCallum Cancer Center, Melbourne, VIC, Australia; and"},{"name":"Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4643-7078","authenticated-orcid":false,"given":"Neeraj","family":"Aryal","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Hattersley","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Shao","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal C.","family":"Saeh","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Fawell","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky W.","family":"Johnstone","sequence":"additional","affiliation":[{"name":"Gene Regulation Laboratory, Research Division, Peter MacCallum Cancer Center, Melbourne, VIC, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Drew","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-4438","authenticated-orcid":false,"given":"Justin","family":"Cidado","sequence":"additional","affiliation":[{"name":"Oncology Bioscience, Oncology R&D, AstraZeneca, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2021052715231033100_B1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2021052715231033100_B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2021052715231033100_B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"2021052715231033100_B4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","article-title":"Recent advances in the development of Mcl-1 inhibitors for cancer therapy","volume":"198","author":"Hird","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2021052715231033100_B5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"18","key":"2021052715231033100_B6","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"issue":"16","key":"2021052715231033100_B7","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2021052715231033100_B8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2021052715231033100_B9","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"2021052715231033100_B10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"issue":"14","key":"2021052715231033100_B11","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-19-1397","article-title":"AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia","volume":"26","author":"Yi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7626","key":"2021052715231033100_B12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"5","key":"2021052715231033100_B13","doi-asserted-by":"crossref","first-page":"180002","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol"},{"issue":"3","key":"2021052715231033100_B14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","article-title":"Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer","volume":"14","author":"Mita","year":"2014","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"2021052715231033100_B15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00280-014-2583-9","article-title":"Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed\/refractory chronic lymphocytic leukemia patients","volume":"74","author":"Fabre","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2021052715231033100_B16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2021052715231033100_B17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1101\/gad.244368.114","article-title":"CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma","volume":"28","author":"Huang","year":"2014","journal-title":"Genes Dev"},{"issue":"19","key":"2021052715231033100_B18","doi-asserted-by":"crossref","first-page":"13663","DOI":"10.1074\/jbc.M600266200","article-title":"The stability and anti-apoptotic function of A1 are controlled by its C terminus","volume":"281","author":"Herold","year":"2006","journal-title":"J Biol Chem"},{"issue":"5","key":"2021052715231033100_B19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41418-018-0169-5","article-title":"TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1","volume":"26","author":"Lionnard","year":"2019","journal-title":"Cell Death Differ"},{"issue":"2","key":"2021052715231033100_B20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11373-005-9064-4","article-title":"Mcl-1: a highly regulated cell death and survival controller","volume":"13","author":"Yang-Yen","year":"2006","journal-title":"J Biomed Sci"},{"issue":"2","key":"2021052715231033100_B21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41418-019-0454-y","article-title":"Characterization of a novel human BFL-1-specific monoclonal antibody","volume":"27","author":"Gangoda","year":"2020","journal-title":"Cell Death Differ"},{"issue":"4","key":"2021052715231033100_B22","first-page":"484","article-title":"Anti-apoptotic role of Bfl-1 in staurosporine-treated B-lymphoblastic cells","volume":"72","author":"Shim","year":"2000","journal-title":"Int J Hematol"},{"issue":"9","key":"2021052715231033100_B23","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/MCB.19.9.5923","article-title":"NF-kappaB induces expression of the Bcl-2 homologue A1\/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis","volume":"19","author":"Wang","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2021052715231033100_B24","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) [published correction appears in Blood Cancer J. 2016;6:e403]","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J"},{"issue":"25","key":"2021052715231033100_B25","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1016\/j.febslet.2005.09.028","article-title":"BH3-ligand regulates access of MCL-1 to its E3 ligase","volume":"579","author":"Warr","year":"2005","journal-title":"FEBS Lett"},{"issue":"22","key":"2021052715231033100_B26","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 Inhibitors: An Update. [published online ahead of print, 2020 Sep 17]","volume":"63","author":"Wu","year":"2020","journal-title":"J Med Chem"},{"issue":"6","key":"2021052715231033100_B27","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1073\/pnas.94.6.2168","article-title":"Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"2021052715231033100_B28","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.271.14.8313","article-title":"Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites","volume":"271","author":"Knudsen","year":"1996","journal-title":"J Biol Chem"},{"key":"2021052715231033100_B29","doi-asserted-by":"crossref","first-page":"212574","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"issue":"8","key":"2021052715231033100_B30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021052715231033100_B31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.chembiol.2016.07.022","article-title":"Selective covalent targeting of anti-apoptotic BFL-1 by cysteine-reactive stapled peptide inhibitors","volume":"23","author":"Huhn","year":"2016","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2021052715231033100_B32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.str.2017.11.016","article-title":"Crystal structures of anti-apoptotic BFL-1 and its complex with a covalent stapled peptide inhibitor","volume":"26","author":"Harvey","year":"2018","journal-title":"Structure"},{"issue":"6","key":"2021052715231033100_B33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.chembiol.2020.04.004","article-title":"Identification of a covalent molecular inhibitor of anti-apoptotic BFL-1 by disulfide tethering","volume":"27","author":"Harvey","year":"2020","journal-title":"Cell Chem Biol"},{"issue":"5","key":"2021052715231033100_B34","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1021\/acs.jmedchem.9b01442","article-title":"Discovery and characterization of 2,5-substituted benzoic acid dual inhibitors of the anti-apoptotic Mcl-1 and Bfl-1 proteins","volume":"63","author":"Kump","year":"2020","journal-title":"J Med Chem"},{"issue":"34","key":"2021052715231033100_B35","doi-asserted-by":"crossref","first-page":"23505","DOI":"10.18632\/oncotarget.25239","article-title":"The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells","volume":"9","author":"Zocchi","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"2021052715231033100_B36","doi-asserted-by":"crossref","first-page":"e59588","DOI":"10.1371\/journal.pone.0059588","article-title":"The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling","volume":"8","author":"Desai","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"2021052715231033100_B37","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leuk Res"},{"issue":"10","key":"2021052715231033100_B38","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1345\/aph.1C404","article-title":"Clinical pharmacology of flavopiridol following a 72-hour continuous infusion","volume":"37","author":"Rudek","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2021052715231033100_B39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/cdd.2016.156","article-title":"Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment","volume":"24","author":"Schenk","year":"2017","journal-title":"Cell Death Differ"},{"issue":"5203","key":"2021052715231033100_B40","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1126\/science.7878471","article-title":"Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice","volume":"267","author":"Motoyama","year":"1995","journal-title":"Science"},{"issue":"1","key":"2021052715231033100_B41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1101\/gad.14.1.23","article-title":"Mcl-1 deficiency results in peri-implantation embryonic lethality","volume":"14","author":"Rinkenberger","year":"2000","journal-title":"Genes Dev"},{"issue":"6","key":"2021052715231033100_B42","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2021052715231033100_B43","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"2021052715231033100_B44","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"key":"2021052715231033100_B45","article-title":"Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL [published online ahead of print 30 June 2020]","author":"Haselager","journal-title":"Blood"},{"issue":"4","key":"2021052715231033100_B46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1101\/gad.13.4.382","article-title":"The prosurvival Bcl-2 homolog Bfl-1\/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis","volume":"13","author":"Zong","year":"1999","journal-title":"Genes Dev"},{"issue":"12","key":"2021052715231033100_B47","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1172\/JCI29401","article-title":"Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes","volume":"116","author":"Piva","year":"2006","journal-title":"J Clin Invest"},{"issue":"3","key":"2021052715231033100_B48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol Cell"},{"issue":"4","key":"2021052715231033100_B49","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"2021052715231033100_B50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"2021052715231033100_B51","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/bloodadvances.2017007856","article-title":"Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance","volume":"1","author":"Stevens","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2021052715231033100_B52","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.151.4.1979","article-title":"Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2","volume":"151","author":"Lin","year":"1993","journal-title":"J Immunol"},{"issue":"2","key":"2021052715231033100_B53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bbrc.1998.9155","article-title":"A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils","volume":"249","author":"Chuang","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"20","key":"2021052715231033100_B54","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/bloodadvances.2019000585","article-title":"The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations","volume":"3","author":"Franzini","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2021052715231033100_B55","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"2021052715231033100_B56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cdd.2011.158","article-title":"BCL2A1: the underdog in the BCL2 family","volume":"19","author":"Vogler","year":"2012","journal-title":"Cell Death Differ"},{"key":"2021052715231033100_B57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biocel.2014.11.015","article-title":"Role of the pro-survival molecule Bfl-1 in melanoma","volume":"59","author":"Hind","year":"2015","journal-title":"Int J Biochem Cell Biol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/21\/2947\/1807920\/bloodbld2020008528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/21\/2947\/1807920\/bloodbld2020008528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:54:18Z","timestamp":1697280858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/21\/2947\/474378\/Targeting-Bfl-1-via-acute-CDK9-inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":57,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008528","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]}}}